<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04124081</url>
  </required_header>
  <id_info>
    <org_study_id>GNI-F351-201503</org_study_id>
    <nct_id>NCT04124081</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interactions Between Hydronidone and Entecavir Capsules in Healthy Chinese Subjects</brief_title>
  <official_title>Pharmacokinetic Interactions Between Hydronidone and Entecavir Capsules in Healthy Chinese Subjects(Single Center, Single Arm, Open, Self - Control)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Continent Pharmaceutical Co, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Continent Pharmaceutical Co, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study, by comparing the Hydronidone capsules and entecavir capsule in a single dose and&#xD;
      steady-state dosing state of both the level of blood drug concentration, assess Hydronidone&#xD;
      capsules and entecavir capsule for interaction。&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Actual">August 13, 2019</completion_date>
  <primary_completion_date type="Actual">June 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma drug concentration</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Compare the difference in plasma drug concentration between single drug and two drug combinations</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hydronidone</condition>
  <arm_group>
    <arm_group_label>Drug group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydronidone capsules&amp; Entecavir capsules</intervention_name>
    <description>take the Hydronidone capsule and then the entecavir capsule, and then take the last two together</description>
    <arm_group_label>Drug group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria：&#xD;
&#xD;
          1. gender: Chinese healthy male subject;&#xD;
&#xD;
          2. age: 18-40 years old, with a difference of no more than 10 years;&#xD;
&#xD;
          3. weight: ≥50kg; Body mass index [= weight kg/ (height m2)] ranged from 19 to 24.&#xD;
&#xD;
          4. the subject (or his/her partner) has no pregnancy plan during and within 6 months&#xD;
             after the trial and voluntarily takes effective physical contraception and has no&#xD;
             sperm donation plan;&#xD;
&#xD;
          5. before the trial, I have had a detailed understanding of the nature, significance,&#xD;
             possible benefits, possible inconveniences and potential risks of the trial, and I&#xD;
             have volunteered to participate in the clinical trial. I am able to communicate well&#xD;
             with the investigator, comply with the requirements of the whole study, and have&#xD;
             signed a written informed consent.&#xD;
&#xD;
        Exclusion criteria：&#xD;
&#xD;
          1. have participated in any other clinical trials within the first three months of the&#xD;
             trial;&#xD;
&#xD;
          2. (preliminary) of any process may affect test security, or drug in the body of the&#xD;
             disease, including but not limited to: heart, liver, kidney, endocrine, the digestive&#xD;
             tract, immune system and respiratory system always or the existing system diseases&#xD;
             (especially cardiovascular diseases including cardiovascular disease risk, any impact&#xD;
             on drug absorption of gastrointestinal diseases (such as irritable bowel syndrome&#xD;
             symptoms, bowel disease or inflammatory bowel disease), active pathological bleeding&#xD;
             (such as peptic ulcer), urticaria, eczema, dermatitis, epilepsy, allergic rhinitis,&#xD;
             asthma, etc.);&#xD;
&#xD;
          3. (consultation) allergy: if there are two or more drugs, food allergy history&#xD;
             (including experimental drugs), lactose intolerance;&#xD;
&#xD;
          4. (consultation) any drugs that inhibit or induce drug metabolism in the liver (common&#xD;
             liver enzyme inducers: barbiturates (phenobarbital is the most common), carbamazepine,&#xD;
             aminoximate, griseofulvin, aminopropyl, phenytoin, gromitol, rifampin, dexamethasone;&#xD;
             Common liver enzyme inhibitors: ampromazine, cimetidine, ciprofloxacin, metronidazole,&#xD;
             chloramphenicol, isoniazid, sulfonamide); Or have used any medicines (including&#xD;
             Chinese herbal medicines) or health supplements within 14 days prior to initial&#xD;
             administration;&#xD;
&#xD;
          5. (consultation) have special requirements on food and cannot follow a uniform diet&#xD;
             (such as intolerance to standard meals) or have difficulty swallowing;&#xD;
&#xD;
          6. (consultation) unable to tolerate venipuncture and/or having a history of blood or&#xD;
             acupuncture;&#xD;
&#xD;
          7. (consultation) patients who have been drinking excessive amounts of tea, coffee or&#xD;
             caffeinated drinks (more than 8 cups a day, 1 cup =250mL) for a long time; Or taking&#xD;
             any food or beverage containing caffeine (such as coffee, strong tea, chocolate, etc.)&#xD;
             within 48 hours before the first administration of the drug;&#xD;
&#xD;
          8. (consultation) previous binge drinking (i.e., male drinking more than 28 units per&#xD;
             week and female drinking more than 21 units per week (1 unit contains 14g alcohol,&#xD;
             such as 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine); Or who had&#xD;
             regularly consumed alcohol (more than 14 units per week) during the 6 months prior to&#xD;
             the trial; Or who had taken any alcoholic product within 24 hours of initial&#xD;
             administration;&#xD;
&#xD;
          9. (consultation) those who had donated blood or suffered massive bleeding (greater than&#xD;
             450 mL) within 3 months before the first administration of the study, or who planned&#xD;
             to donate blood or blood components during the study period or within 3 months after&#xD;
             the end of the study;&#xD;
&#xD;
         10. (consultation) acute disease during the screening phase before study or before study&#xD;
             medication;&#xD;
&#xD;
         11. (consultation) patients who had taken food or drinks containing enzymes that can&#xD;
             induce or inhibit liver metabolism (e.g., grapefruit, mango, pitaya, grape juice,&#xD;
             orange juice, etc., rich in flavonoids or citrus glycosides) within 24 hours before&#xD;
             the first administration were studied;&#xD;
&#xD;
         12. (consultation) those who have had surgery within three months before the screening&#xD;
             period, or who are planning to have surgery during the study period, and those who&#xD;
             have had surgery that will affect drug absorption, distribution, metabolism and&#xD;
             excretion;&#xD;
&#xD;
         13. (consultation) previous history of drug abuse; A history of drug abuse;&#xD;
&#xD;
         14. (consultation) those who have smoked more than 5 cigarettes per day in the 14 days&#xD;
             before screening, or who cannot stop using any tobacco products during the trial;&#xD;
&#xD;
         15. screening for smoking or using any tobacco products up to admission;&#xD;
&#xD;
         16. screening phase physical examination, measurement of vital signs, electrocardiogram&#xD;
             examination, laboratory examination [blood routine, urine routine, blood biochemistry,&#xD;
             blood coagulation function], and the investigator judged abnormal patients with&#xD;
             clinical significance;&#xD;
&#xD;
         17. those with positive nicotine test results;&#xD;
&#xD;
         18. alcohol breath test with test results greater than 0.0mg/100ml;&#xD;
&#xD;
         19. positive urine drug screening;&#xD;
&#xD;
         20. hepatitis b surface antigen positive, or hepatitis c antibody positive, or syphilis&#xD;
             spirochete antibody positive, or HIV antibody positive;&#xD;
&#xD;
         21. the investigator considers that there are any circumstances that may affect the&#xD;
             subject's informed consent or adherence to the study protocol, or participation in the&#xD;
             study may affect the study results or their own safety.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ethics committee of drug clinical trials of huazhong university of science and technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2019</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

